Compare Icl Group Ltd (ICL) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

ICL trades at $5.00, down 0.99% over 24 hours, with a bearish technical signal. The company reported Q1 2026 earnings of $0.11 per share, beating estimates, and recently completed an $800 million senior notes offering. Revenue for 2025 was $7.15 billion with a net income margin of 3.15%, while valuation ratios show a P/E of 24.05 and P/S of 0.88. Analyst consensus is entirely hold-rated, reflecting cautious sentiment amid mixed financial trends.

The outlook for ICL is neutral with modest growth potential, supported by operational improvements and raised 2026 EBITDA guidance. Key risks include elevated raw material costs, foreign exchange headwinds, and competitive pressures in the specialty minerals sector. Investors should weigh stable cash flows against margin compression and debt levels from recent financing activities.

Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.

Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.